New Zealand markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
198.61-5.72 (-2.80%)
At close: 4:00PM EDT
198.61 0.00 (0.00%)
After hours: 04:39PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2020
31/12/2019
31/12/2018
31/12/2017
Total revenue
687,534
492,853
219,750
74,908
89,912
Cost of revenue
114,638
78,052
25,062
1,802
-
Gross profit
572,896
414,801
194,688
73,106
-
Operating expenses
Research development
698,786
654,819
655,114
505,420
390,635
Selling general and administrative
625,945
588,420
479,005
382,359
199,365
Total operating expenses
1,324,731
1,243,239
1,134,119
887,779
590,000
Operating income or loss
-751,835
-828,438
-939,431
-814,673
-500,088
Interest expense
123,179
84,496
-
-
-
Total other income/expenses net
-12,666
45,525
20,730
24,737
-3,022
Income before tax
-883,657
-855,600
-885,253
-760,674
-490,874
Income tax expense
3,024
2,681
863
823
-
Income from continuing operations
-886,681
-858,281
-886,116
-761,497
-490,874
Net income
-886,681
-858,281
-886,116
-761,497
-490,874
Net income available to common shareholders
-886,681
-858,281
-886,116
-761,497
-490,874
Basic EPS
-
-7.46
-8.11
-7.57
-5.42
Diluted EPS
-
-7.46
-8.11
-7.57
-5.42
Basic average shares
-
114,986
109,264
100,590
90,554
Diluted average shares
-
114,986
109,264
100,590
90,554
EBITDA
-
-736,332
-922,256
-808,238
-486,721